PerkinElmer to buy Oxford Immunotec Global

By staff writers

January 7, 2021 -- PerkinElmer plans to acquire Oxford Immunotec Global and that company's infectious disease testing technology in a deal worth $591 million. The purchase is expected to close in the first half of 2021.

The acquisition will help PerkinElmer expand its infectious disease testing portfolio to include tuberculosis detection, giving it access to Oxford Immunotec's T-cell immunology technology for testing latent tuberculosis, it said.

Oxford Immunotec reported total revenue of U.S. $73.7 million in fiscal year 2019 and U.S. $39.2 million in the nine months ended September 30, 2020.

Once the deal closes, Oxford Immunotec will become a privately held firm, PerkinElmer said.

PerkinElmer receives CE Mark for SARS-CoV-2 assay
PerkinElmer has received a CE Mark for its SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) assay. Now, saliva can be designated...
PerkinElmer newborn screening test gets CE Mark
PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.
PerkinElmer debuts dried blood spot-based COVID-19 serology test
PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G antibodies using its genetic screening processor/dissociation-enhanced...
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
PerkinElmer says it's not target of federal probe
PerkinElmer on May 18 said that while the company had received subpoenas from federal investigators looking into healthcare fraud at medical labs, the...

Copyright © 2021

Last Updated ls 1/7/2021 1:01:50 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current